BioNTech will seek to follow its successful Covid-19 vaccine with a shot to prevent malaria, both its first solo project and first new infectious-disease effort since the pandemic began. The German biotech aims to start patient trials of a malaria shot by the end of next year. Backed by the World Health Organization, European Commission and the kENUP Foundation, the project will simultaneously seek to build out the infrastructure necessary to produce any successful malaria shot, as well as other messenger RNA vaccines, in Africa, BioNTech CEO Ugur Sahin said.
from Engineering News | Home https://ift.tt/3rCph5F
